What did @trulykellyxx actually say?
In her week two Mounjaro update, @trulykellyxx walked through her injection routine, sharing that you "prime in the needle each week, not the pen" with Mounjaro, using two clicks. She described injecting into the stomach area at least five centimeters from the belly button, holding the pen until it reads zero, then waiting a further ten seconds. She also said the medication can be kept at room temperature for up to 30 days before disposal, should always be stored away from sunlight, and must be clear, never cloudy or colored. On the experience side, she mentioned switching from a GLP-1 at 2.4mg to Mounjaro 2.5mg, not expecting much at the lower dose, and reporting reduced appetite with no side effects after one week.
Does the science back this up?
For the most part, yes. The injection technique she describes lines up with Eli Lilly's prescribing information for tirzepatide. The two-click priming step is specific to the KwikPen-style autoinjector, and it is needle-level priming, not device-level, which is a genuinely useful distinction she got right. The five-centimeter navel clearance is standard subcutaneous injection guidance. The 30-day room temperature limit is also accurate, consistent with Lilly's published storage data.
On the pharmacology side, her reduced appetite in week one at 2.5mg is biologically plausible. Tirzepatide acts on both GIP and GLP-1 receptors. Even at the starting dose, receptor engagement is meaningful. Farzana et al. (2023, Diabetes Care) noted appetite suppression appearing in the earliest weeks of tirzepatide treatment, though individual response varies considerably. The observation that hunger returned the following day is also consistent with the drug's half-life of approximately five days, meaning plasma levels fluctuate across the week.
What did they get wrong (or right)?
She got the storage and priming instructions largely right, which matters more than it sounds. Incorrect priming is a real source of underdosing in autoinjector medications. One small inaccuracy: she says "just sunlight" when describing what to protect the medication from. In reality, Lilly's guidance specifies protection from light broadly, not only direct sunlight, and also from heat above 30 degrees Celsius. Storing it in a window-adjacent room on a warm day could degrade the peptide even without direct sun exposure.
Her claim that she switched from a 2.4mg GLP-1 to Mounjaro 2.5mg and "wasn't expecting much" because it is a lower dose reflects a common misconception. Tirzepatide and semaglutide are not dose-equivalent. You cannot compare milligram figures across different drug classes. Framing 2.5mg tirzepatide as lower than 2.4mg semaglutide suggests a direct numerical equivalence that does not exist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 5mg already producing meaningful weight loss, and the 2.5mg starting dose is a tolerability ramp, not an ineffective dose.
What should you actually know?
If you are starting Mounjaro, the injection mechanics she describes are worth paying attention to. Subcutaneous autoinjector errors, particularly around priming and injection site rotation, are underreported causes of inconsistent dosing. The abdomen, thigh, and upper arm are all validated injection sites in clinical literature, and rotating between them reduces localized lipohypertrophy over time.
What this video does not cover, and what any new user should understand, is that the 2.5mg starting dose is a tolerability protocol, not a therapeutic ceiling. The SURMOUNT-1 trial ran participants up to 15mg over time, and the dose escalation schedule exists for a reason: gastrointestinal side effects, including nausea, vomiting, and diarrhea, are significantly more common at higher doses. The fact she reports no side effects at week one of 2.5mg is not surprising. It does not predict how she will tolerate dose increases. Anyone managing their own expectations based on week one should know that the experience often changes significantly at 5mg and above.
One final point: her experience is anecdotal and specific to her body, her activity level, and her hormonal cycle, which she herself acknowledges. GLP-1 and GIP receptor agonist responses vary considerably between individuals. Jastreboff et al. (2022) reported a mean weight loss of 20.9% at the highest tirzepatide dose over 72 weeks, but the range was wide. Some participants responded far less. Week two is not predictive of long-term outcome.